WuXi
Through its collaboration with WuXi, Aceso Therapeutics aims to accelerate and secure ACT-101’s CMC development, supported by WuXi’s recognized global expertise and comprehensive capabilities in pharmaceutical development.
ILIFE
By collaborating with ILIFE, Aceso Therapeutics aims to anticipate the design of ACT-101’s clinical study synopsis and secure this next development stage by leveraging the recognized clinical expertise of ILIFE’s team.
Leads to Development
By collaborating with L2D, Aceso Therapeutics aims to advance ACT-101’s regulatory development efficiently and securely, supported by the recognized expertise of L2D’s team.
AXLR
By partnering with NanoPharm company of Aptar Pharma group, Aceso Therapeutics aims to accelerate and secure the development of ACT-101 while reinforcing the program’s unique technological value and inhalation delivery expertise.